Shamburg News · 8-K filed Nov 13, 2026, 8:35 AM EST
Xenetic Biosciences Reports Third Quarter 2026 Results and Proposed Santersus Share Exchange
XBIO · Xenetic Biosciences, Inc.
- Earnings
- Material agreement
- Acquisition
- Materiality: high
Xenetic Biosciences reported a net loss of approximately $1.7 million, or $0.72 per basic and diluted share, for the quarter ended September 30, 2026, compared with approximately $0.5 million, or $0.33 per share, a year earlier. Royalty revenue decreased approximately 29% to approximately $0.7 million, while general and administrative expenses rose approximately 138% to approximately $1.9 million, primarily due to advisory costs tied to the proposed share exchange with Santersus AG. Cash and cash equivalents totaled approximately $5.8 million as of September 30, 2026. The company also disclosed a definitive all-stock share exchange agreement with Santersus AG, expected to close in the first quarter of 2027 subject to Xenetic stockholder approval.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001683168-26-008650.
Written from the filing by Shamburg Markets. Figures are as reported by the company.